Surufatinib Combined With TAS-102 in Third-line and Later-line Therapy of Patients With Advanced Pancreatic Cancer

Summary

This is a single-center, single-arm, open-label, phase 2 clinical study, to explore the efficacy and safety of surufatinib combined with TAS-102 in third-line and later-line therapy of patients with advanced pancreatic cancer

Timeline

Start

2023-01-30

Primary completion

2025-03-31

Completion

2025-05-10

Publications

• Lu Y, Lin Q, Mo Y, Liu F, Zhang M, Huang R, Wang Y, Wang Y, Wang Z, Luo H, Guo G, Chen J, Liu Y, He M, Wang F, Wang F, Zhang D. Efficacy and safety of TAS-102 plus Surufatinib in third and later line metastatic pancreatic cancer: a prospective, single center and biomarker exploratory, phase II study. Mol Cancer. 2025 Oct 2;24(1):235. doi: 10.1186/s12943-025-02437-0.

Drugs

Indications